GlassScriptPhysician profile
Douglas Craig Olsen
NPI 1235273616
$13,337.77
in general payments reported to CMS, 2019-2025
36 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,548 · 2020: $2,066 · 2021: $2,780 · 2022: $2,097 · 2023: $1,900 · 2024: $1,372 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,846.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,892.16 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Amgen INC. | $1,750.43 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,559.47 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,286.39 | 2021-2025 | |
| Pfizer INC. | $891.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $775.41 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novo Nordisk INC | $682.09 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $550.42 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $475.99 | 2019-2025 | Trintellix |
| Lundbeck LLC | $401.45 | 2020-2023 | Rexulti |
| Amarin Pharma, INC. | $393.73 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $393.01 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $329.10 | 2021-2025 | Caplyta |
| Allergan, INC. | $277.21 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $238.16 | 2019-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.